Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | PI4KA | P42356 | 3/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | SCN4A | P35499 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30136461 | 1.00 | RAB9A (0.40) | RAB9AMAPTAXLGFERHRH3 | |
| SCHEMBL2666929 | 0.83 | RAB9A (0.42) | RAB9AMAPTAXLGFERGAA | |
| SCHEMBL3710272 | 0.81 | P2RY1 (0.41) | RAB9ASMN1; SMN2ALDH1A1NPC1LMNA | |
| SCHEMBL12042139 | 0.77 | HRH3 (0.41) | HRH3 | |
| SCHEMBL35211844 | 0.77 | HRH3 (0.41) | HRH3 | |
| SCHEMBL799228 | 0.75 | RAB9A (0.41) | RAB9AMAPTAXLGFERGAA | |
| SCHEMBL30858903 | 0.75 | AXL (0.48) | RAB9AMAPTAXLGFERGAA | |
| SCHEMBL558903 | 0.75 | AXL (0.48) | RAB9AMAPTAXLGFERGAA | |
| SCHEMBL11999657 | 0.75 | RAB9A (0.40) | RAB9AMAPTAXLGFERGAA | |
| SCHEMBL5533108 | 0.75 | RAB9A (0.48) | RAB9AMAPTAXLGFERGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676480-A1 | INHIBITORS OF DNA POLYMERASE THETA | Breakpoint Therapeutics GmbH (DE) | 2026-01-14 | — | — | EP | disclosed |
| US-20260007680-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2026-01-08 | — | — | US | disclosed |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4547672-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20250129100-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | HUTCHISON MEDIPHARMA LTD (CN) | 2025-03-27 | — | — | US | disclosed |
| US-12162895-B2 | DNA polymerase theta inhibitor for treatment of cancer | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-12-10 | — | — | US | disclosed |
| US-12145945-B2 | Compounds, compositions, and therapeutic uses thereof | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-11-19 | — | — | US | disclosed |
| US-20240336628-A1 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-10-10 | — | — | US | disclosed |
| US-20240327431-A1 | DNA POLYMERASE THETA INHIBITOR FOR TREATMENT OF CANCER | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| US-7514439-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-7514439-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-7513916-B2 | Agents for coloring keratin fibers | THE PROCTER & GAMBLE COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| WO-2008119734-A2 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| WO-2007097930-A1 | AGENTS FOR COLORING KERATIN FIBERS | THE PROCTER & GAMBLE COMPANY (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070199160-A1 | Agents for coloring keratin fibers | THE PROCTER & GAMBLE COMPANY | 2007-08-30 | — | — | US | disclosed |
| EP-1825883-A1 | Agents for coloring keratin fibers | Wella Aktiengesellschaft (DE) | 2007-08-29 | — | — | EP | disclosed |
| EP-1820537-A1 | Agents for coloring keratin fibers | Wella Aktiengesellschaft (DE) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162895-B2 | DNA polymerase theta inhibitor for treatment of cancer | POLQ, POLB, POLH | RAB9A 3225/4885MAPT 1209/4885AXL 4552/4885 |
| US-20260007680-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | RAB9A 1082/4885MAPT 4801/4885AXL 4128/4885 |
| US-20250129100-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | RAB9A 2519/4885MAPT 3215/4885AXL 3982/4885 |
| US-20240336628-A1 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | POLQ, POLK, POLB | RAB9A 1764/4885MAPT 1489/4885AXL 4734/4885 |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | GCK, KHK, GCKR | RAB9A 4012/4885MAPT 4489/4885AXL 354/4885 |
| US-20240327431-A1 | DNA POLYMERASE THETA INHIBITOR FOR TREATMENT OF CANCER | POLQ, POLB, POLH | RAB9A 3225/4885MAPT 1209/4885AXL 4552/4885 |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | RAB9A 2519/4885MAPT 3215/4885AXL 3982/4885 |
| US-12145945-B2 | Compounds, compositions, and therapeutic uses thereof | POLQ, POLK, POLB | RAB9A 2158/4885MAPT 1441/4885AXL 4630/4885 |
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | KCNJ11, NISCH, CYP4Z1 | RAB9A 4795/4885MAPT 3267/4885AXL 4163/4885 |
| US-20070199160-A1 | Agents for coloring keratin fibers | KRT18, IK, KRTCAP2 | RAB9A 3182/4885MAPT 781/4885AXL 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.